Search

Congenital Myopathy with tremor, currently classified as Congenital Myopathy-16, represents a very rare disease phenotype, associated with domain-specific variants in the MYBPC1 gene. This gene encodes Myosin binding protein-C slow (sMyBP-C), a cytoskeletal protein expressed in skeletal muscle tissues with at least 10 different isoforms. This protein plays a crucial role in stabilizing the thick filament and regulating actin-myosin binding during cross-bridge formation. Previous research has suggested that observed sarcomeric deficits may underlie the molecular mechanisms causing the disease. We have created a mouse model for this disease, harboring a patient-specific variant (c.739T>C, p.(Y247H)). Here, we present a comprehensive description of the observed phenotype using a plethora of quantitative and qualitative methods, including behavioral tests, microscopy, protein quantification, biochemical assays including spectrophotometric measurements of OXPHOS enzyme activities, transcriptome analysis by RNA-seq, and proteomics. Our findings demonstrate strength deficits, myogenic tremor, and homozygous lethality in the model, as well as the localization of the mutant protein, similar to a previous model, carrying another patient-specific variant in the MYBPC1 gene. While we observed expected sarcomere disorder and misalignment, they were not as pronounced. Transcriptome data and biochemical assays unveil not only morphological abnormalities in mitochondria but also functional deficits in the oxidative phosphorylation system. This research reinforces the myogenic tremor phenotype observed in patients and the initial animal model, emphasizing the correlation between phenotypic severity and alterations in the binding potential of the mutant protein, as suggested in our previous work. Additionally, we provide evidence indicating mitochondrial dysregulation as a component of this disease. We thank ERAF Nr. 1.1.1.1/18/A/097. [ABSTRACT FROM AUTHOR]

Background: Somatic and germline genetic alterations are significant drivers of cancer. Increasing integration of new technologies which profile these alterations requires timely, equitable and high-quality genetic counselling to facilitate accurate diagnoses and informed decision-making by patients and their families in preventive and clinical settings. This article aims to provide an overview of genetic counselling legislation and practice across European Union (EU) Member States to serve as a foundation for future European recommendations and action., Methods: National legislative databases of all 27 Member States were searched using terms relevant to genetic counselling, translated as appropriate. Interviews with relevant experts from each Member State were conducted to validate legislative search results and provide detailed insights into genetic counselling practice in each country., Results: Genetic counselling is included in national legislative documents of 22 of 27 Member States, with substantial variation in legal mechanisms and prescribed details (i.e. the 'who, what, when and where' of counselling). Practice is similarly varied. Workforce capacity (25 of 27 Member States) and genetic literacy (all Member States) were common reported barriers. Recognition and/or better integration of genetic counsellors and updated legislation and were most commonly noted as the 'most important change' which would improve practice., Conclusions: This review highlights substantial variability in genetic counselling across EU Member States, as well as common barriers notwithstanding this variation. Future recommendations and action should focus on addressing literacy and capacity challenges through legislative, regulatory and/or strategic approaches at EU, national, regional and/or local levels., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Public Health Association.)

The PTCD3 gene product (protein PTCD3 or MRPS39) forms the entry channel of the mitochondrial small ribosomal subunit and binds to single-stranded mRNA. Here, we expand on the clinical manifestations of PTCD3 pathogenic variants by describing an early-onset patient with Leigh-like syndrome and two patients with milder form of disease, with combined oxidative phosphorylation deficiency. A 34-year-old male and his 33-year-old sister both have horizontal nystagmus, pronounced rough tremor, truncal ataxia, dysmetria, spasticity and hyperreflexia. The basal respiration rate decreased significantly for the male patient and his mother ( p  < 0.0001) compared to the controls. The whole genome sequencing analysis revealed two heterozygous variants in the PTCD3 : c.1182T>A, p.(Tyr394Ter) and c.805C>T, p.(His269Tyr). Tyr394Ter variant ablates the C-terminal half of the protein, including a significant portion of the central fold. In silico modelling for the variant His269Tyr shows that the inclusion of the slightly larger tyrosine sidechain is well tolerated, with no significant change in either the position or the movement of the surrounding area. The third case is a 9-year-old boy, who has a global developmental delay, central hypotonia, hyperreflexia and abnormal MRI. PTCD3 pathogenic variant c.538+4A>G was identified by whole exome sequencing. To test the variant's effect on splicing, an RT-PCR experiment was performed, which revealed skipping of an out-of-frame exon 7., Competing Interests: The authors declare no conflicts of interest., (© 2024 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.)

Variants of mitochondrial DNA (mtDNA) have been identified as risk factors for the development of Parkinson's disease (PD). However, the underlying pathogenetic mechanisms remain unclear. Cybrid models carrying various genotypes of mtDNA variants were tested for resistance to PD-simulating MPP + treatment. The most resistant line was selected for transcriptome profiling, revealing specific genes potentially influencing the resistant characteristic. We then conducted protein validation and molecular biological studies to validate the related pathways as the influential factor. Cybrids carrying the W3 mtDNA haplogroup demonstrated the most resistance to the MPP + treatment. In the transcriptome study, PPP1R15A was identified, while further study noted elevated expressions of the coding protein GADD34 across all cybrids. In the study of GADD34-related mitochondrial unfolding protein response (mtUPR), we found that canonical mtUPR, launched by the phosphate eIF2a, is involved in the resistant characteristic of specific mtDNA to MPP + treatment. Our study suggests that a lower expression of GADD34 in the late phase of mtUPR may prolong the mtUPR process, thereby benefitting protein homeostasis and facilitating cellular resistance to PD development. We herein demonstrate that GADD34 plays an important role in PD development and should be further investigated as a target for the development of therapies for PD.